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ABSTRACT
Background
Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib
(Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons
encoding the kinase domain of the epidermal growth factor receptor (EGFR). Despite initial
responses, patients eventually progress by unknown mechanisms of ‘‘acquired’’ resistance.
Methods and Findings
We show that in two of five patients with acquired resistance to gefitinib or erlotinib,
progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a
secondary mutation in exon 20, which leads to substitution of methionine for threonine at
position 790 (T790M) in the kinase domain. Tumor cells from a sixth patient with a drug-
sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete
resection also contained the T790M mutation. This mutation was not detected in untreated
tumor samples. Moreover, no tumors with acquired resistance had KRAS mutations, which have
been associated with primary resistance to these drugs. Biochemical analyses of transfected
cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M
mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.
Interestingly, a mutation analogous to T790M has been observed in other kinases with acquired
resistance to another kinase inhibitor, imatinib (Gleevec).
Conclusion
In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant
subclones containing an additional EGFR mutation emerge in the presence of drug. This
observation should help guide the search for more effective therapy against a specific subset of
lung cancers.
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Somatic gain-of-function mutations in exons encoding the
epidermal growth factor receptor (EGFR) tyrosine kinase
domain are found in about 10% of non-small cell lung
cancers (NSCLCs) from the United States [1,2,3], with higher
percentages observed in east Asia [2,4,5,6]. Some 90% of
NSCLC-associated mutations occur as either multi-nucleo-
tide in-frame deletions in exon 19, involving elimination of
four amino acids, Leu-Arg-Glu-Ala, or as a single nucleotide
substitution at nucleotide 2573 (TﬁG) in exon 21, resulting
in substitution of arginine for leucine at position 858
(L858R). Both of these mutations are associated with
sensitivity to the small-molecule kinase inhibitors geﬁtinib
or erlotinib [1,2,3]. Unfortunately, nearly all patients who
experience marked improvement on these drugs eventually
develop progression of disease. While KRAS mutations have
been associated with some cases of primary resistance to
geﬁtinib or erlotinib [7], mechanisms underlying ‘‘acquired’’
or ‘‘secondary’’ resistance are unknown.
Acquired resistance to kinase-targeted anticancer therapy
has been most extensively studied with imatinib, an inhibitor
of the aberrant BCR-ABL kinase, in chronic myelogenous
leukemia (CML). Mutations in the ABL kinase domain are
found in 50%–90% of patients with secondary resistance to
the drug (reviewed in [8]). Such mutations, which cluster in
four distinct regions of the ABL kinase domain (the ATP
binding loop, T315, M351, and the activation loop), interfere
with binding of imatinib to ABL [9,10,11]. Crystallographic
studies of various ABL mutants predict that most should
remain sensitive to inhibitors that bind ABL with less
stringent structural requirements. Using this insight, new
small-molecule inhibitors have been identiﬁed that retain
activity against the majority of imatinib-resistant BCR-ABL
mutants [12,13].
Although imatinib inhibits different kinases in various
diseases (BCR-ABL in CML, KIT or PDGFR-alpha in gastro-
intestinal stromal tumors [GISTs], and PDGFR-alpha in
hypereosinophilic syndrome [HES]) (reviewed in [14]), some
tumors that become refractory to treatment with imatinib
appear to have analogous secondary mutations in the kinase-
coding domain of the genes encoding these three enzymes.
For example, in CML, a commonly found mutation is a CﬁT
single nucleotide change that replaces threonine with
isoleucine at position 315 (T315I) in the ABL kinase domain
[9,10,11]. In GIST and HES, respectively, the analogous T670I
mutation in KIT and T674I mutation in PDGFR-alpha have
been associated with acquired resistance to this drug [15,16].
To determine whether lung cancers that acquire clinical
resistance to either geﬁtinib or erlotinib display additional
mutations in the EGFR kinase domain, we have examined the
status of EGFR exons 18 to 24 in tumors from ﬁve patients
who initially responded but subsequently progressed while on
these drugs. These exons were also assessed in tumor cells
from a sixth patient whose disease rapidly recurred while on
geﬁtinib therapy after complete gross tumor resection.
Because of the association of KRAS mutations with primary
resistance to geﬁtinib and erlotinib [7], we also examined the
status of KRAS in tumor cells from these six patients. In an
effort to explain the selective advantage of cells with a newly
identiﬁed ‘‘resistance’’ mutation in EGFR—a T790M amino
acid substitution—we further characterized the drug sensi-
tivity of putatively resistant EGFR mutants versus wild-type or
drug-sensitive EGFR mutants, using both a NSCLC cell line
fortuitously found to contain the T790M mutation and lysates
from cells transiently transfected with wild-type and mutant
EGFR cDNAs.
Methods
Tissue Procurement
Tumor specimens, including parafﬁn blocks, ﬁne needle
biopsies, and pleural effusions, were obtained through
protocols approved by the Institutional Review Board of
Memorial Sloan-Kettering Cancer Center (protocol 92–055
[7] and protocol 04–103 [Protocol S1]). All patients provided
informed consent.
Mutational Analyses of EGFR and KRAS in Lung Tumors
Genomic DNA was extracted from tumor specimens, and
primers for EGFR (exons 18–24) and KRAS2 (exon 2) analyses
were as published [3,7]. All sequencing reactions were
performed in both forward and reverse directions, and all
mutations were conﬁrmed at least twice from independent
PCR isolates.
A speciﬁc exon 20 mutation (T790M) was also detected by
length analysis of ﬂuorescently labeled (FAM) PCR products
on a capillary electrophoresis device (ABI 3100 Avant,
Applied Biosystems, Foster City, California, United States),
based on a new NlaIII restriction site created by the T790M
mutation (2369 CﬁT), using the following primers: EGFR
Ex20F, 59-FAM-CTCCCTCCAGGAAGCCTACGTGAT-39 and
EGFR Ex20R 59-TTTGCGATCTGCACACACCA-39.U s i n g
serially mixed dilutions of DNA from NSCLC cell lines
(H1975, L858R- and T790M-positive; H-2030, EGFR wild-
type) for calibration, this assay detects the presence of the
T790M mutation when H1975 DNA comprises 3% or more of
the total DNA tested, compared to a sensitivity of 6% for
direct sequencing (data not shown).
RT-PCR
The following primers were used to generate EGFR cDNA
fragments spanning exon 20: EGFR 2095F 59-CCCAAC-
CAAGCTCTCTTGAG-39 and EGFR 2943R 59-ATGACAAGG-
TAGCGCTGGGGG-39. PCR products were ligated into
plasmids using the TOPO TA-cloning kit (Invitrogen,
Carlsbad, California, United States), as per manufacturer’s
instructions. Minipreps of DNA from individual clones were
sequenced using the T7 priming site of the cloning vector.
Functional Analyses of Mutant EGFRs
Two numbering systems are used for EGFR. The ﬁrst
denotes the initiating methionine in the signal sequence as
amino acid  24. The second, used here, denotes the
methionine as amino acid þ1. Commercial suppliers of
antibodies, such as the Y1068-speciﬁc anti-phospho-EGFR,
use the ﬁrst nomenclature. To be consistent, we consider
Y1068 as Y1092. Likewise, the T790M mutation reported here
has also been called T766M. Mutations were introduced into
full-length wild-type and mutant EGFR cDNAs using a
QuikChange Site-Directed Mutagenesis Kit (Stratagene, La
Jolla, California, United States) and cloned into expression
vectors as described [3]. The following primers were used to
generate the deletion (del) L747–E749;A750P mutant: for-
ward 59-TAAAATTCCCGTCGCTATCAAGGAGCCAA-
PLoS Medicine | http://www.plosmedicine.org March 2005 | Volume 2 | Issue 3 | e73 0226
Resistance to EGFR Kinase InhibitorsCATCTCCGAAAGCCAACAAGG-39 and reverse 59-
CCTTGTTGGCTTTCGGAGATGTTGGCTCCTTGATAGC-
GACGGGAATTTTA-39. The following primers were used to
introduce the T790M mutation: forward 59-AGCTCATCATG-
CAGCTCAT-39 and reverse 59-ATGAGCTGCATGAT-
GAGCT-39. The L858R mutant cDNA was generated
previously [3]. All mutant clones were fully re-sequenced
bidirectionally to ensure that no additional mutations were
introduced. Various EGFRs were transiently expressed in
293T human embryonic kidney cells as published [3]. Cells
were treated with different concentrations of geﬁtinib or
erlotinib.
Immunoblotting
See methods and supplementary methods in [3] for details
on cell lysis, immunoblotting, and antibody reagents. At least
three independent experiments were performed for all
analyses.
Cell Culture
The NSCLC cell lines H1650, H1975, H2030, H2347, H2444,
H358, and H1734 were purchased from American Type
Culture Collection (Manassas, Virginia, United States). H3255
was a gift of B. Johnson and P. Janne. Cells were grown in
complete growth medium (RPMI-1640; American Type
Culture Collection catalog no. 30–2001) supplemented with
10% fetal calf serum, 10 units/ml penicillin, and 10 lg/ml
streptomycin) at 37 8C and 5% CO2. For viability studies, cells
were seeded in complete growth medium in black 96-well
clear bottom ViewPlates (PerkinElmer, Wellesley, Massachu-
setts, United States) at a density of 5,000 (H1975 and H2030)
or 7,500 cells per well (H3255). Following overnight incuba-
tion, cells were grown for 24 h in the supplemented RPMI-
1640 medium with 0.1% serum. Cells (in supplemented RPMI-
1640 medium containing 0.1% serum) were then incubated
for 48 h in the continued presence of geﬁtinib or erlotinib.
Viability Assay
Cell viability was assayed using Calcein AM (acetoxymethyl
ester of Calcein, Molecular Probes, Eugene, Oregon, United
States). Following incubation with geﬁtinib or erlotinib,
monolayers were washed twice with PBS (containing calcium
and magnesium) and incubated with 7.5 lmol Calcein AM in
supplemented RPMI-1640 (no serum) for 30 min. Labeling
medium was removed, and cells were washed three times with
PBS. Calcein ﬂuorescence (Ex, 485 nm; Em, 535 nM) was
detected immediately using a Victor V multi-label plate
reader (PerkinElmer). Three independent experiments were
performed for each cell line; each experiment included four
to eight replicates per condition.
Results
Case Reports
We identiﬁed secondary EGFR mutations in three of six
individuals whose disease progressed on either geﬁtinib or
erlotinib (Table 1). Brief case histories of these three patients
are presented below.
Patient 1. This 63-y-old female ‘‘never smoker’’ (smoked
less than 100 cigarettes in her lifetime) initially presented
with bilateral diffuse chest opacities and a right-sided pleural
effusion. Transbronchial biopsy revealed adenocarcinoma.
Disease progressed on two cycles of systemic chemotherapy,
after which geﬁtinib, 250 mg daily, was started. Comparison
of chest radiographs obtained prior to starting geﬁtinib
(Figure S1A, left panel) and 2 wk later (Figure S1A, middle
panel) showed dramatic improvement. Nine months later, a
chest radiograph revealed progression of disease (Figure S1A,
right panel). Subsequently, the patient underwent a com-
puted tomography (CT)–guided biopsy of an area in the right
lung base (Figure 1A, left panel). Despite continued treatment
with geﬁtinib, either with chemotherapy or at 500 mg daily,
the pleural effusion recurred, 12 mo after initiating geﬁtinib
(Figure 1A, right panel). Pleural ﬂuid was obtained for
molecular studies. In total, this patient had three tumor
specimens available for analysis: the original lung tumor
biopsy, a biopsy of the progressing lung lesion, and pleural
ﬂuid. However, re-review of the original transbronchial
biopsy showed that it had scant tumor cells (Table 1).
Patient 2. This 55-y-old woman with a nine pack-year
history of smoking underwent two surgical resections within
2 y (right lower and left upper lobectomies) for bronchio-
loalveolar carcinoma with focal invasion. Two years later, her
disease recurred with bilateral pulmonary nodules and
further progressed on systemic chemotherapy. Thereafter,
the patient began erlotinib, 150 mg daily. A baseline CT scan
of the chest demonstrated innumerable bilateral nodules
(Figure S1B, left panel), which were markedly reduced in
number and size 4 mo after treatment (Figure S1B, middle
Table 1. Specimens Analyzed in This Study for Mutations in the EGFR Tyrosine Kinase Domain (Exons 18 to 24) and KRAS (Exon 2)
Patient Pathology Specimen Analyzed Date Obtained Percent Tumor Cells
a EGFR KRAS
1 Transbronchial biopsy Day 0 Scant Wild-type Wild-type
Progressing lung lesion 12 mo .85% L858R þ T790M Wild-type
Pleural effusion 14 mo .85% L858R þ T790M Wild-type
2 Original lung lesion Day 0 .85% del L747–E749;A750P Wild-type
Progressing spine lesion 75 mo .85% del L747–E749;A750P þ T790M Wild-type
Progressing lung lesion 77 mo .85% del L747–E749;A750P þ T790M Wild-type
3 Original pleural biopsy Day 0 n/a Unavailable Unavailable
Re-resection lung lesion 68 mo .85% del E746–A750 Wild-type
Pleural effusion 76 mo .50% del E746–A750 þ T790M Wild-type
The transbronchial biopsy in patient 1 had scant tumor cells; sequencing analysis revealed only wild-type sequence (see text).
aPercent tumor cells is defined by assessment of corresponding histopathological slides.
n/a, not applicable.
DOI: 10.1371/journal.pmed.0020073.t001
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was decreased to 100 mg daily owing to fatigue. At 23 mo of
treatment with erlotinib, a CT scan demonstrated an
enlarging sclerotic lesion in the thoracic spine. The patient
underwent CT-guided biopsy of this lesion (Figure 1B, left
panel), and the erlotinib dose was increased to 150 mg daily.
After 25 mo of treatment, she progressed within the lung
(Figure S1B, right panel). Erlotinib was discontinued, and a
ﬂuoroscopically guided core needle biopsy was performed at
a site of progressive disease in the lung (Figure 1B, right
panel). In total, this patient had three tumor specimens
available for analysis: the original resected lung tumor, the
biopsy of the enlarging spinal lesion, and the biopsy of the
progressing lung lesion (Table 1).
Patient 3. This 55-y-old female ‘‘never smoker’’ was treated
for nearly 4.5 y with weekly paclitaxel and trastuzumab [17]
for adenocarcinoma with bronchioloalveolar carcinoma
features involving her left lower lobe, pleura, and mediastinal
lymph nodes. Treatment was discontinued owing to fatigue.
Subsequently, the patient underwent surgical resection.
Because of metastatic involvement of multiple mediastinal
lymph nodes and clinical features known at that time to be
predictive of response to geﬁtinib (female, never smoker,
bronchioloalveolar variant histology), she was placed on
‘‘adjuvant’’ geﬁtinib 1 mo later (Figure S1C, left panel). This
drug was discontinued after 3 mo when she developed a new
left-sided malignant pleural effusion (Figure S1C, middle
panel). Despite drainage and systemic chemotherapy, the
pleural effusion recurred 4 mo later (Figure S1C, right panel),
at which time pleural ﬂuid was collected for analysis. In total,
this patient had two clinical specimens available for analysis:
tumor from the surgical resection and pleural ﬂuid (Table 1).
Patients’ Tumors Contain EGFR Tyrosine Kinase Domain
Mutations Associated with Sensitivity to EGFR Tyrosine
Kinase Inhibitors
We screened all available tumor samples from these three
patients for previously described drug-sensitive EGFR muta-
tions, by direct DNA sequencing of exons 19 and 21 [3].
Tumor samples from patient 1 showed a TﬁG change at
nucleotide 2573, resulting in the exon 21 L858R amino acid
substitution commonly observed in drug-responsive tumors.
This mutation was present in the biopsy material from the
progressing lung lesion (Figure S2A, upper panels) and from
cells from the pleural effusion (Figure S2A, lower panels),
both of which on cytopathologic examination consisted of a
majority of tumor cells (Table 1). Interestingly, comparisons
of the tracings suggest that an increase in copy number of the
mutant allele may have occurred. Speciﬁcally, while the ratio
of wild-type (nucleotide T) to mutant (nucleotide G) peaks at
position 2573 was approximately 1:1 or 1:2 in the lung biopsy
specimen (Figure S2A, upper panels), sequencing of DNA
from the pleural ﬂuid cells demonstrated a dominant mutant
G peak (Figure S2A, lower panels). Consistent with this, a
single nucleotide polymorphism (SNP) noted at nucleotide
2361 (A or G) demonstrated a corresponding change in the
ratios of A:G, with a 1:1 ratio in the transbronchial biopsy,
and a nearly 5:1 ratio in the pleural ﬂuid (Figure 2A). Notably,
we did not detect the 2573 TﬁG mutation in the original
transbronchial biopsy specimen (Table 1; data not shown). As
stated above, this latter specimen contained scant tumor cells,
most likely fewer than needed for detection of an EGFR
mutation by direct sequencing (see [7]).
All three specimens from patient 2, including the original
lung tumor and the two metastatic samples from bone and
lung, showed an exon 19 deletion involving elimination of 11
nucleotides (2238–2248) and insertion of two nucleotides, G
and C (Figure S2B, all panels; Table 1). These nucleotide
changes delete amino acids L747–E749 and change amino
acid 750 from alanine to proline (A750P). A del L747–
E749;A750P mutation was previously reported with different
nucleotide changes [2]. In all samples from patient 2, the wild-
type sequence predominated at a ratio of about 3:1 over the
mutant sequence.
Both of the available tumor samples from patient 3
contained a deletion of 15 nucleotides (2236–2250) in exon
19 (Table 1; data not shown), resulting in elimination of ﬁve
amino acids (del E746–A750). This speciﬁc deletion has been
previously reported [3]. The ratio of mutant to wild-type
peaks was approximately 1:1 in both specimens (data not
shown).
Collectively, these results demonstrate that tumors from all
three patients contain EGFR mutations associated with
sensitivity to the tyrosine kinase inhibitors geﬁtinib and
erlotinib. In addition, these data show that within individual
patients, metastatic or recurrent lesions to the spine, lung,
and pleural ﬂuid contain the same mutations. These latter
observations support the idea that relapsing and metastatic
tumor cells within individuals are derived from original
progenitor clones.
Figure 1. Re-Biopsy Studies
(A.) Patient 1. CT-guided biopsy of progressing lung lesions after 10
mo on geﬁtinib (left panel). Two months later, ﬂuid from a right-
sided pleural effusion (right panel) was collected for molecular
analysis.
(B) Patient 2. CT-guided biopsy of a progressing thoracic spine lesion
(left panel) and ﬂuoroscopic-guided biopsy of a progressing lung
lesion (right panel). The biopsy needles are indicated by white arrows.
DOI: 10.1371/journal.pmed.0020073.g001
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Domain Detected in Lesions That Progressed while on
Treatment with Either Gefitinib or Erlotinib
To determine whether additional mutations in the EGFR
kinase domain were associated with progression of disease in
these patients, we performed direct sequencing of all of the
exons (18 through 24) encoding the EGFR catalytic region in
the available tumor specimens.
Analysis of patient 1’s pre-geﬁtinib specimen, which
contained scant tumor cells (Table 1; see above), not
surprisingly showed only wild-type EGFR sequence (Table 1;
data not shown). However, careful analysis of the exon 20
sequence chromatograms in both forward and reverse
directions from this patient’s lung biopsy specimen obtained
after disease progression on geﬁtinib demonstrated an
additional small peak at nucleotide 2369, suggesting a CﬁT
mutation (Figure 2A, upper panels; Table 1). This nucleotide
change leads to substitution of methionine for threonine at
position 790 (T790M). The 2369 CﬁT mutant peak was even
more prominent in cells from the patient’s pleural ﬂuid,
which were obtained after further disease progression on
geﬁtinib (Figure 2A, lower panels; Table 1). The increase in
the ratio of mutant to wild-type peaks obtained from analyses
of the lung specimen and pleural ﬂuid paralleled the increase
in the ratio of the mutant G peak (leading to the L858R
mutation) to the wild-type T peak at nucleotide 2573 (see
above; Figure S2A), as well as the increase in the ratio of the
A:G SNP at position 2361 (Figure 2A). Collectively, these
ﬁndings imply that the exon 20 T790M mutation was present
on the same allele as the exon 21 L858R mutation, and that a
subclone of cells harboring these mutations emerged during
drug treatment.
In patient 2, the tumor-rich sample obtained prior to
treatment with erlotinib did not contain any additional
mutations in the exons encoding the EGFR tyrosine kinase
domain (Figure 2B, upper panels; Table 1). By contrast, her
progressing bone and lung lesions contained an additional
small peak at nucleotide 2369, suggesting the existence of a
subclone of tumor cells with the same CﬁT mutation
observed in patient 1 (Figure 2B, middle and lower panels;
Figure 2. Sequencing Chromatograms with the T790M EGFR Exon 20 Mutation in Various Clinical Specimens and the NSCLC Cell Line H1975
(A–C) In all three patients—patient 1 (A), patient 2 (B), and patient 3 (C)—the secondary T790M mutation was observed only in lesions obtained
after progression on either geﬁtinib or erlotinib.
(D) Cell line H1975 contains both an exon 21 L858R mutation (upper panel) and the exon 20 T790M mutation (lower panel). The asterisks
indicate a common SNP (A or G) at nucleotide 2361; the arrows indicate the mutation at nucleotide 2369 (CﬁT), which leads to substitution of
methonine (ATG) for threonine (ACG) at position 790. In the forward direction, the mutant T peak is blue. In the reverse direction, the mutant
peak is green, while the underlying blue peak represents an ‘‘echo’’ from the adjacent nucleotide.
DOI: 10.1371/journal.pmed.0020073.g002
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these latter two samples appeared to correlate with the
relative size of the corresponding peaks of the exon 19
deletion (Figure S2B). Interestingly, the SNP at nucleotide
2361 (A or G) was detected in specimens from patient 2
before but not after treatment with erlotinib, suggesting that
one EGFR allele underwent ampliﬁcation or deletion during
the course of treatment (Figure S2B).
Patient 3 showed results analogous to those of patient 2. A
tumor-rich pre-treatment specimen did not demonstrate
EGFR mutations other than the del E746–A750 exon 19
deletion; speciﬁcally, in exon 20, no secondary changes were
detected (Figure 2C, upper panels; Table 1). However,
analysis of DNA from cells in the pleural effusion that
developed after treatment with geﬁtinib showed the CﬁT
mutation at nucleotide 2369 in exon 20 (Figure 2C, lower
panels; Table 1), corresponding to the T790M mutation
described above. There was no dramatic change between the
two samples in the ratio of the A:G SNP at position 2361.
The mutant 2369 T peak was small, possibly because geﬁtinib
had been discontinued in this patient for 4 mo at the time
pleural ﬂuid tumor cells were collected; thus, there was no
selective advantage conferred upon cells bearing the T790M
mutation.
To determine whether the 2369 CﬁT mutation was a
previously overlooked EGFR mutation found in NSCLCs, we
re-reviewed exon 20 sequence tracings derived from analysis
of 96 fresh-frozen resected tumors [3] and 59 parafﬁn-
embedded tumors [7], all of which were removed from
patients prior to treatment with an EGFR tyrosine kinase
inhibitor. We did not detect any evidence of the T790M
mutation in these 155 tumors (data not shown; see Dis-
cussion). Collectively, our results suggest that the T790M
mutation is associated with lesions that progress while on
geﬁtinib or erlotinib. Moreover, at least in patients 1 and 2,
the subclones of tumor cells bearing this mutation probably
emerged between the time of initial treatment with a tyrosine
kinase inhibitor and the appearance of drug resistance.
In three additional patients (case histories not described
here) with lung adenocarcinomas who improved but sub-
sequently progressed on therapy with either geﬁtinib or
erlotinib, we examined DNA from tumor specimens obtained
during disease progression. In all three patients, we found
EGFR mutations associated with drug sensitivity (all exon 19
deletions). However, we did not ﬁnd any additional mutations
in exons 18 to 24 of EGFR, including the CﬁT change at
position 2369 (data not shown). These results imply that
alternative mechanisms of acquired drug resistance exist.
Patients’ Progressive Tumors Lack KRAS Mutations
Mutations in exon 2 of KRAS2 occur in about one-fourth of
NSCLCs. Such mutations rarely, if ever, accompany EGFR
mutations and are associated with primary resistance to
geﬁtinib or erlotinib [7]. To evaluate the possibility that
secondary KRAS mutations confer acquired resistance to
these drugs, we performed mutational proﬁling of KRAS2
exon 2 from tumor specimens from patients 1 to 3, as well as
the three additional patients lacking evidence of the T790M
mutation. None of the specimens contained any changes in
KRAS (Table 1; data not shown), indicating that KRAS
mutations were not responsible for drug resistance and
tumor progression in these six patients.
An Established NSCLC Cell Line Also Contains Both T790M
and L858R Mutations
We proﬁled the EGFR tyrosine kinase domain (exons 18 to
24) and KRAS exon 2 in eight established NSCLC lines (Table
2). Surprisingly, one cell line—H1975—contained the same
CﬁT mutation at position 2369 (T790M) as described above
(Figure 2D, lower panel). This cell line had previously been
shown by others to contain a 2573 TﬁG mutation in exon 21
(L858R) [18], which we conﬁrmed (Figure 2D, upper panel); in
addition, H1975 was reported to be more sensitive to
geﬁtinib inhibition than other lung cancer cell lines bearing
wild-type EGFR [18]. Only exons 19 and 21 were apparently
examined in this published study.
In our own analysis of H1975 (exons 18 to 24), the mutant
2369 T peak resulting in the T790M amino acid substitution
was dominant, suggesting an increase in copy number of the
mutant allele in comparison to the wild-type allele. The ratio
of mutant to wild-type peaks was similar to that of the mutant
2573 G (corresponding to the L858R amino acid substitution)
to wild-type T peaks (Figure 2D, all panels), implying that the
T790M and L858R mutations were in the same ampliﬁed
allele. To further investigate this possibility, we performed
RT-PCR to generate cDNAs that spanned exon 20 of EGFR
and included sequences from exon 19 and 21. PCR products
were then cloned, and individual colonies were analyzed for
EGFR mutations. Sequencing chromatograms of DNA from
four of four clones showed both the 2369 CﬁT and 2573
TﬁG mutations, conﬁrming that both mutations were in the
same allele (data not shown).
Other NSCLC cell lines carried either EGFR or KRAS
mutations, but none had both (Table 2). As reported, H3255
contained an L858R mutation [19] and H1650 contained an
exon 19 deletion [18]. No other cell lines analyzed contained
additional mutations in the exons encoding the EGFR
tyrosine kinase domain.
A Novel PCR Restriction Fragment Length Polymorphism
Assay Independently Confirms the Absence or Presence of
the T790M Mutation
As stated above, the mutant peaks suggestive of a T790M
mutation in exon 20 were small in some sequence chromato-
grams. To eliminate the possibility that these peaks were due
to background ‘‘noise,’’ we sought to conﬁrm the presence of
the 2369 CﬁT mutation in speciﬁc samples, by developing an
Table 2. Status of NSCLC Cell Lines Analyzed for EGFR Tyrosine
Kinase Domain (Exons 18 to 24) and KRAS (Exon 2) Mutations
Cell Line EGFR KRAS
H1650 del E746–A750 Wild-type
H3255 L858R Wild-type
H1975 L858R þ T790M Wild-type
H2030 Wild-type G12C
H358 Wild-type G12C
H2444 Wild-type G12V
H1734 Wild-type G13C
H2347 Wild-type L19F
See Methods for further details.
DOI: 10.1371/journal.pmed.0020073.t002
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that takes advantage of a PCR restriction fragment length
polymorphism (PCR-RFLP) generated by the speciﬁc mis-
sense mutation. After PCR ampliﬁcation with exon-20-
speciﬁc primers spanning nucleotide 2369, wild-type se-
quence contains speciﬁc NlaIII sites, which upon digestion
yield a 106-bp product (see Methods; Figure 3A). Presence of
the mutant 2369 T nucleotide creates a new NlaIII restriction
digest site, yielding a slightly shorter product (97 bp), readily
detected by ﬂuorescent capillary electrophoresis. This test is
about 2 -fold more sensitive than direct sequencing (see
Methods; data not shown).
We ﬁrst used DNA from the H1975 cell line (which contains
both T790M and L858R mutations) to conﬁrm the speciﬁcity
of the PCR-RFLP assay. As expected, analysis of these cells
produced both the 97- and 106-bp fragments. By contrast,
analysis of DNA from H2030 (which contains wild-type EGFR;
Table 2) showed only the 106-bp fragment (Figure 3A). These
data show that this test can readily indicate the absence or
presence of the mutant allele in DNA samples. However, this
test was only semi-quantitative, as the ratio of the mutant 97-
bp product versus the wild-type 106-bp product varied in
independent experiments from approximately 1:1 to 2:1.
We next used this PCR-RFLP assay to assess various patient
samples for the presence of the speciﬁc 2369 CﬁT mutation
corresponding to the T790M amino acid substitution. DNA
from the progressing bone and lung lesions in patient 1
produced both the 97- and 106-bp fragments, but DNA from
the original lung tumor did not (Figure 3B). The ratio of
mutant to wild-type products was higher in the cells from the
pleural ﬂuid, consistent with the higher peaks seen on the
chromatograms from direct sequencing of exon 20 (see
Figure 2A). Likewise, DNA from progressive lesions from
patients 2 and 3 yielded both 97- and 106-bp fragments in the
PCR-RFLP assay (Figure 3B), whereas the pre-treatment
specimens did not produce the 97-bp product. Collectively,
these data from an independent assay conﬁrm that the
T790M mutation was present in progressing lesions from all
three patients. We were also unable to detect the T790M
mutation in any specimens from the three additional patients
with acquired resistance that failed to demonstrate secondary
mutations in EGFR exons 18 to 24 by direct sequencing (data
not shown).
Biochemical Properties of EGFR Mutants
To determine how the T790M mutation would affect EGFR
proteins already containing mutations associated with sensi-
tivity to EGFR tyrosine kinase inhibitors, we introduced the
speciﬁc mutation into EGFR cDNAs that encoded the exon 21
and 19 mutations found in patients 1 and 2, respectively.
Corresponding proteins ([i] L858R and L858R plus T790M,
[ii] del L747–E749;A750P and del L747–E749;A750P plus
T790M, and [iii] wild-type EGFR and wild-type EGFR plus
T790M) were then produced by transient transfection with
expression vectors in 293T cells, which have very low levels of
endogenous EGFR [3]. Various lysates from cells that were
serum-starved and pre-treated with geﬁtinib or erlotinib
were analyzed by immunoblotting. Amounts of total EGFR (t-
EGFR) were determined using an anti-EGFR monoclonal
antibody, and actin served as an indicator of relative levels of
protein per sample. To assess the drug sensitivity of the
various EGFR kinases in surrogate assays, we used a Y1092-
phosphate-speciﬁc antibody (i.e., phospho-EGFR [p-EGFR])
to measure the levels of ‘‘autophosphorylated’’ Tyr-1092 on
EGFR in relation to levels of t-EGFR protein. We also assessed
the global pattern and levels of induced tyrosine phosphor-
ylation of cell proteins by using a generalized anti-phospho-
tyrosine reagent (RC-20).
Geﬁtinib inhibited the activity of wild-type and L858R
EGFRs progressively with increasing concentrations of drug,
as demonstrated by a reduction of tyrosine-phosphorylated
proteins (Figure 4A) and a decrease in p-EGFR:t-EGFR ratios
(Figure 4B). By contrast, wild-type and mutant EGFRs
containing the T790M mutation did not display a signiﬁcant
change in either phosphotyrosine induction or p-EGFR:t-
EGFR ratios (Figure 4A and 4B). Similar results were obtained
using erlotinib against wild-type and del E747–L747;A750P
EGFRs in comparison to the corresponding mutants con-
taining the T790M mutation (Figure 4C). These results
Figure 3. A Novel PCR-RFLP Assay Independently Confirms Presence of
the T790M Mutation in Exon 20 of the EGFR Kinase Domain
(A) Design of the assay (see text for details). ‘‘F’’ designates the
ﬂuorescent label, FAM. At the bottom of this panel, the assay
demonstrates with the 97-bp NlaIII cleavage product the presence of
the T790M mutation in the H1975 cell line; this product is absent in
H2030 DNA. The 106-bp NlaIII cleavage product is generated by
digestion of wild-type EGFR.
(B) The PCR-RFLP assay demonstrates that pre-drug tumor samples
from the three patients lack detectable levels of the mutant 97-bp
product, while specimens obtained after disease progression contain
the T790M mutation. Pt, patient.
DOI: 10.1371/journal.pmed.0020073.g003
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geﬁtinib or erlotinib to inhibit EGFR tyrosine kinase activity,
even in EGFR mutants (i.e., L858R or an exon 19 deletion)
that are clinically associated with drug sensitivity.
Resistance of a NSCLC Cell Line Harboring Both T790M
and L858R Mutations to Gefitinib or Erlotinib
To further explore the functional consequences of the
T790M mutation, we determined the sensitivity of various
NSCLC cells lines grown in the presence of either geﬁtinib or
erlotinib, using an assay based upon Calcein AM. Uptake and
retention of this ﬂuorogenic esterase substrate by vehicle-
versus drug-treated live cells allows for a comparison of
relative cell viability among cell lines [20]. The H3255 cell
line, which harbors the L858R mutation and no other EGFR
TK domain mutations (Table 2), was sensitive to treatment
with geﬁtinib, with an IC50 of about 0.01 lmol (Figure 5). By
contrast, the H1975 cell line, which contains both L858R and
T790M mutations (Table 2), was approximately 100-fold less
sensitive to drug, with an IC50 of about 1 lmol (Figure 5). In
fact, the sensitivity of H1975 cells was more similar to that of
H2030, which contains wild-type EGFR (exons 18 to 24) and
mutant KRAS (Figure 5). Very similar results were obtained
with erlotinib (Figure S3).
Discussion
Speciﬁc mutations in the tyrosine kinase domain of EGFR
are associated with sensitivity to either geﬁtinib or erlotinib,
but mechanisms of acquired resistance have not yet been
reported. Based upon analogous studies in other diseases with
another kinase inhibitor, imatinib, a single amino acid
substitution from threonine to methionine at position 790
in the wild-type EGFR kinase domain was predicted to lead to
drug resistance, even before the association of exon 19 and 21
mutations of EGFR with drug responsiveness in NSCLC was
reported. The T790M mutation was shown in vitro in the
context of wild-type EGFR to confer resistance to geﬁtinib
[21] and a related quinazoline inhibitor, PD153035 [22].
We show here, through molecular analysis of tumor
material from three patients and one NSCLC cell line, as
Figure 4. EGFR Mutants Containing the T790M Mutation Are Resistant to
Inhibition by Gefitinib or Erlotinib
293T cells were transiently transfected with plasmids encoding wild-
type (WT) EGFR or EGFR mutants with the following changes:
T790M, L858R, L858R þ T790M, del L747–E749;A750P, or del L747–
E749;A750P þ T790M. After 36 h, cells were serum-starved for 24 h,
treated with geﬁtinib or erlotinib for 1 h, and then harvested for
immunoblot analysis using anti-p-EGFR (Y1092), anti-t-EGFR, anti-
phosphotyrosine (p-Tyr), and anti-actin antibodies as described in
Methods. The EGFR T790M mutation, in conjunction with either
wild-type EGFR or the drug-sensitive L858R EGFR mutant, prevents
inhibition of tyrosine phosphorylation (A) or p-EGFR (B) by geﬁtinib.
Analogously, the T790M mutation, in conjunction with the drug-
responsive del L747–E749;A750P EGFR mutant, prevents inhibition
of p-EGFR by erlotinib (C).
DOI: 10.1371/journal.pmed.0020073.g004
Figure 5. Sensitivity to Gefitinib Differs Among NSCLC Cell Lines
Containing Various Mutations in EGFR or KRAS
The three indicated NSCLC cell lines, H3255 (L858R mutation),
H1975 (both T790M and L858R mutations), and H2030 (wild-type
EGFR, mutant KRAS) (see Table 2), were grown in increasing
concentrations of geﬁtinib, and the density of live cells after 48 h
of treatment was measured using a Calcein AM ﬂuorescence assay.
Fluorescence in vehicle-treated cells is expressed as 100%. Results are
the mean 6 standard error of three independent experiments in
which there were four to eight replicates of each condition. Similar
results were obtained with erlotinib (see Figure S3).
DOI: 10.1371/journal.pmed.0020073.g005
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drug resistance to geﬁtinib or erlotinib is indeed associated
with the T790M mutation. Importantly, we ﬁnd that the
T790M mutation confers drug resistance not just to wild-type
EGFR but also to mutant EGFRs associated with clinical
responsiveness to EGFR tyrosine kinase inhibitors [1,2,3]. Our
results further demonstrate that an analogous mechanism of
acquired resistance exists for imatinib and EGFR tyrosine
kinase inhibitors (Table 3), despite the fact that the various
agents target different kinases in distinct diseases.
In tumors from patients not treated with either geﬁtinib or
erlotinib, the 2369 CﬁT mutation (T790M) appears to be
extremely rare. We have not identiﬁed this mutation in 155
tumors (see above), and among nearly 1,300 lung cancers in
which analysis of EGFR exons 18 to 21 has been performed
[1,2,3,4,5,6], only one tumor (which also harbored an L858R
mutation) was reported to contain the T790M mutation.
Whether the patient from which this tumor was resected had
received geﬁtinib or erlotinib is unclear, and the report did
not note an association with acquired resistance to either
drug [5].
How tumor cells bearing the T790M mutation emerge
within geﬁtinib- or erlotinib-treated patients is a matter of
investigation. Subclones bearing this mutation could arise de
novo during treatment. However, based upon analogous
studies in CML, it is also possible that NSCLC subclones
bearing this secondary mutation pre-exist within the primary
tumor clone in individual patients, albeit at low frequency
[23]. In either scenario, treatment with geﬁtinib or erlotinib
subsequently allows these resistant subclones to become
apparent, because most cells bearing sensitivity-conferring
mutations die, while cells with the T790M mutation persist.
From analysis of the crystal structure of the EGFR kinase
domain bound to erlotinib, it is has been shown that the wild-
type threonine residue at position 790 is located in the
hydrophobic ATP-binding pocket of the catalytic region,
where it forms a critical hydrogen bond with the drug [24].
The related compound, geﬁtinib, is predicted to interact with
this threonine residue as well. Substitution of the threonine
at position 790 by a larger residue like methionine would
probably result in steric clash with the aromatic moieties on
these two drugs [25]. By contrast, ATP would likely not
depend on the accessibility of the same hydrophobic cavity
and is therefore probably not affected by the incorporation
of a bulky methionine side chain [25]. Consistent with this,
the T790M mutation has been shown not to abrogate the
catalytic activity of wild-type EGFR [22].
The T790M mutation could also affect the kinase activity or
alter the substrate speciﬁcity of mutant EGFRs, such that a
proliferative advantage would be conferred upon cells
bearing the mutation. Consistent with this, the H1975 NSCLC
cell line reported here to contain both T790M and L858R did
not to our knowledge undergo any prior treatment with
geﬁtinib or erlotinib; the doubly mutated cells must have
become dominant over time through multiple passages in
vitro. This scenario could explain the seemingly contra-
dictory report by others who found the H1975 cell line to be
highly sensitive to geﬁtinib [18]; our H1975 cells could
represent a subclone that emerged over time. Analysis of
earlier passages of H1975 cells for the T790M mutation would
be informative in this regard.
Recently, new small-molecule inhibitors have been identi-
ﬁed that retain activity against the majority of imatinib-
resistant BCR-ABL mutants. The new drugs bind to ABL in an
‘‘open’’ conformation, as opposed to imatinib, which binds
ABL in a ‘‘closed’’ conformation [12,13]. Analogously, it may
be possible to ﬁnd EGFR tyrosine kinase inhibitors that bind
to the EGFR kinase domain in different ways than geﬁtinib
and erlotinib. For example, the crystal structure of another
EGFR inhibitor, lapatinib (GW572016), was recently solved
bound to EGFR [26]. This study revealed that the quinazoline
rings of erlotinib and lapatinib interact differently with the
EGFR kinase domain, suggesting that while the T790M
mutation may affect inhibition by erlotinib and geﬁtinib, it
may not affect inhibition of EGFR by compounds similar to
lapatinib. To our knowledge, no NSCLC patient who initially
responded to but then progressed on either geﬁtinib or
erlotinib has yet been treated with lapatinib.
In some of the patient specimens analyzed, the actual
sequencing peaks demonstrating the T790M mutation were
smaller than originally anticipated. These results differ from
those of acquired resistance mutation in CML [10], GIST
[15,27], and HES [16]. However, in contrast to all of these
diseases, in which tumor cells are readily accessible, lung-
cancer-related tumors are more difﬁcult to access, as
illustrated by the limited manner in which we were able to
obtain tumor cells from various sites of disease (see Figure 1).
Moreover, re-biopsy of patients with lung cancer is not
routinely performed. The use of position emission tomog-
raphy scans to identify the most metabolically active lesions
for biopsy could possibly circumvent this factor in the future,
as long as such lesions are resectable. Additionally, as more
molecularly tailored treatment options become available for
lung cancer, re-biopsy of progressive sites of disease should
become a standard procedure, especially for patients on
clinical trials of targeted agents.
Since tumor specimens from three additional patients with
acquired resistance to EGFR tyrosine kinase inhibitors did
not demonstrate the T790M mutation, this speciﬁc lesion
does not account for all mechanisms of acquired resistance to
Table 3. Analogous Mutations in Four Kinases Associated with Resistance to Kinase Inhibitors
Protein Mutation Disease Drug Reference
BCR-ABL T315I CML Imatinib 11
PDGFR-alpha T674I HES Imatinib 16
KIT T670I GIST Imatinib 15
EGFR T790M NSCLC Gefitinib and erlotinib This study
DOI: 10.1371/journal.pmed.0020073.t003
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Resistance to EGFR Kinase Inhibitorsgeﬁtinib or erlotinib. Given the paradigm established with
imatinib, other drug-resistance mutations in EGFR, either
within or outside the tyrosine kinase domain, are likely to
exist. It is also possible that EGFR ampliﬁcation itself plays a
role in acquired resistance, since imatinib-resistant clones
have been shown to lack resistance mutations but contain
ampliﬁed copies of BCR-ABL [11,28]. Nonetheless, studies
presented here provide a basis for the rational development
of ‘‘second generation’’ kinase inhibitors for use in NSCLC.
Supporting Information
Figure S1. Imaging Studies from Patients 1, 2, and 3
(A) Patient 1. Serial chest radiographs from before (day 0) and during
geﬁtinib treatment (14 d and 9 mo), demonstrating initial response
and subsequent progression.
(B) Patient 2. Serial CT studies of the chest before (day 0) and during
erlotinib treatment (4 mo and 25 mo), demonstrating initial response
and subsequent progression.
(C) Patient 3. Serial chest radiographs before (day 0) and during
adjuvant geﬁtinib treatment (3 mo), following complete resection of
grossly visible disease. The left-sided pleural effusion seen at 3 mo
recurred 4 mo later, at which time ﬂuid was collected for molecular
analysis.
Found at DOI: 10.1371/journal.pmed.0020073.sg001 (951 KB PPT).
Figure S2. Sequencing Chromatograms with the EGFR Exon 19 and
21 Mutations Identiﬁed in Patients 1 and 2
(A) Status of EGFR exon 21 in tumor specimens from patient 1. DNA
from the growing lung lesion and the pleural effusion demonstrated a
heterozygous TﬁG mutation at position 2573, leading to the
common L858R amino acid substitution.
(B) All three specimens from patient 2 showed the same heterozygous
exon 19 deletion, removing residues 747–749 and changing the
alanine at position 750 to proline.
Found at DOI: 10.1371/journal.pmed.0020073.sg002 (104 KB PPT).
Figure S3. Sensitivity to Erlotinib Differs among NSCLC Cell Lines
Containing Various Mutations in EGFR or KRAS
See legend for Figure 5.
Found at DOI: 10.1371/journal.pmed.0020073.sg003 (153 KB PPT).
Protocol S1. Memorial Sloan-Kettering Cancer Center IRB Protocol
04–103
Found at DOI: 10.1371/journal.pmed.0020073.sd003 (566 KB PDF).
Accession Numbers
The LocusLink (http://www.ncbi.nlm.nih.gov/LocusLink/) accession
number for the KRAS2 sequence discussed in this paper is 3845;
the GenBank (http://www.ncbi.nlm.nih.gov/Genbank/) accession num-
ber for the KRAS2 sequence discussed in this paper is
NT_009714.16. Reference EGFR sequence was obtained from
LocusLink accession number 1956 and GenBank accession number
NT_033968.
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Patient Summary
Background. Normal cells in our body have safety mechanisms that
keep them from growing out of control. Tumor cells have somehow
found ways around these safety mechanisms, in some cases through
activating particular growth-promoting genes. One of these, the EGFR
gene, is often activated in lung cancer. Two drugs, gefitinib (also known
as Iressa) and erlotinib (also called Tarceva), have been developed to
inhibit activated EGFR, and studies have shown that they can shrink
tumors in some patients. Most patients who respond to these drugs
have tumors that carry an alteration (or mutation) in the EGFR gene,
which somehow makes their tumors responsive to the drugs.
Why Was This Study Done? In those patients in whom the drugs work,
the tumors shrink initially, but after a while they stop responding and the
cancer comes back. The cancer has, as researchers describe it, become
resistant to the drugs. Understanding how tumors become resistant is
important to develop new and better drugs.
What Did the Researchers Do? They asked patients who initially
responded to erlotinib or gefitinib but then became resistant to consent
to studies allowing further analysis of tumor tissue during and after drug
treatment. They then re-examined the EGFR gene in these tumor
samples.
What Did They Find? They found that tumors from all patients carried
mutations in the EGFR gene that are known to make them responsive to
the drugs. In addition, three of the post-treatment tumors had an
identical second mutation in their EGFR gene. Biochemical studies
showed that these secondary alterations made the original drug-
sensitive EGFR less sensitive to drug treatment. The numbers are small
but suggest that this secondary resistance mutation could be quite
common. Tumor cells from the three other patients didn’t have this
mutation, which suggests that there are other ways for lung cancers to
become resistant to gefitinib and erlotinib.
What Next? Larger studies are needed to confirm that this particular
mutation is a major cause of resistance against the two drugs. It is also
important to find out what causes resistance in the other cases. And
knowing about this resistance mutation will help researchers to develop
drugs that will work even against tumors with the mutation.
More Information Online The following pages contain some informa-
tion on the EGFR kinase inhibitors.
U. S. Food and Drug Administration information page on Iressa
(gefitinib): http://www.fda.gov/cder/drug/infopage/iressa/iressaQ&A.htm
Cancer Research UK information page about erlotinib (Tarceva): http://
www.cancerhelp.org.uk/help/default.asp?page=10296
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